Merial and Transgene sign a collaboration agreement to develop products for animal health

As part of the collaboration, Merial will conduct feasibility studies of different recombinant viruses in veterinary target species, and will have the right to execute an exclusive worldwide license for products originating from the research process. The agreement provides for non-material payments to Transgene during the research phase.

"We are very pleased to enter into this new collaboration with Merial, one of the world's leading innovation-driven animal health companies," said Jean-François Carmier, Chief Executive Officer of Transgene. "This agreement is an opportunity to expand the applications of our vector platform in the field of veterinary medicine".

"Merial is pleased to be working with Transgene in this important area," said Kevin Schultz, Global Head of Merial Research and Development. "Our collaboration with Transgene will expand Merial's ability to conduct research on promising recombinant vectors, which play an important role in our R&D strategy."